SG11202000086PA - Mpo inhibitors for use in medicine - Google Patents
Mpo inhibitors for use in medicineInfo
- Publication number
- SG11202000086PA SG11202000086PA SG11202000086PA SG11202000086PA SG11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cambridge
- pct
- oaa
- july
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
FigureAverage MDA staining by flow cytometric analysis MDA staining total andrology N=29 P<0.01 r (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) vitivio VIII oviolo nonnit Env Hs (19) World Intellectual Property Organization International Bureau (10) International Publication Number WO 2019/016074 Al (43) International Publication Date 24 January 2019 (24.01.2019) WIP0 I PCT (51) International Patent Classification: A61K 31/505 (2006.01) A61P 15/10 (2006.01) (21) International Application Number: PCT/EP2018/068992 (22) International Filing Date: 12 July 2018 (12.07.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/533,448 17 July 2017 (17.07.2017) US (71) Applicant: ASTRAZENECA AB [SE/SE]; 151 85 Sodertalje (SE). (72) Inventors: WHITTAKER, Andrew; 1 Francis Crick Av- enue, Cambridge Biomedical Campus, Cambridge Cam- bridgeshire CB2 OAA (GB). SANGANEE, Hitesh, Jayan- tilal; 1 Francis Crick Avenue, Cambridge Biomedical Cam- pus, Cambridge Cambridgeshire CB2 OAA (GB). 1-1 N 1-1 C (74) Agent: LEESE, Mathew, Paul; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) (54) Title: MPO INHIBITORS FOR USE IN MEDICINE Pdg Sp'? rm a Sit= N euro b SO' ,10 +Ai) C SpErm 4r4.1 1-1 (57) : The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same. C [Continued on next page] WO 2019/016074 Al IMIOHOMMIDERIDIEDIUMMIEDIRMIEMMOVOIMIE Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762533448P | 2017-07-17 | 2017-07-17 | |
PCT/EP2018/068992 WO2019016074A1 (en) | 2017-07-17 | 2018-07-12 | Mpo inhibitors for use in medicine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000086PA true SG11202000086PA (en) | 2020-02-27 |
Family
ID=62904484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000086PA SG11202000086PA (en) | 2017-07-17 | 2018-07-12 | Mpo inhibitors for use in medicine |
Country Status (15)
Country | Link |
---|---|
US (2) | US11246870B2 (en) |
EP (1) | EP3654983B1 (en) |
JP (1) | JP7220193B2 (en) |
KR (1) | KR20200029513A (en) |
CN (1) | CN110891572B (en) |
AU (1) | AU2018304508B2 (en) |
BR (1) | BR112019026270A2 (en) |
CA (1) | CA3068910A1 (en) |
EA (1) | EA202090266A1 (en) |
ES (1) | ES2963315T3 (en) |
IL (1) | IL272043B (en) |
MA (1) | MA49618A (en) |
SG (1) | SG11202000086PA (en) |
WO (1) | WO2019016074A1 (en) |
ZA (1) | ZA202000904B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200029513A (en) | 2017-07-17 | 2020-03-18 | 아스트라제네카 아베 | MPO inhibitors for use in medicine |
AU2020363903A1 (en) * | 2019-10-10 | 2022-03-24 | Biohaven Therapeutics Ltd. | Prodrugs of myeloperoxidase inhibitors |
CN115403584B (en) * | 2021-05-26 | 2024-04-02 | 长春金赛药业有限责任公司 | 2-thio-2, 3-dihydropyrimidine-4-one derivatives, pharmaceutical compositions, preparation methods and applications thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
SE0201193D0 (en) * | 2002-04-19 | 2002-04-19 | Astrazeneca Ab | Novel use |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
EA200800260A1 (en) | 2005-07-05 | 2008-06-30 | ЭДИЛЕЙД ФЭТИЛИТИ СЭНТЭ ПиТиУай ЭлТиДи | The methods, compositions and combination products for the improvement of reproductive health in males or improve the outcome of pregnancy in a female, sperm (Options), process for its preparation and animal organisms that do not belong to the human race, will appear in the result of fertilization of sperm SHOWN |
AR066936A1 (en) | 2007-06-13 | 2009-09-23 | Astrazeneca Ab | 3 - (2R - TETRAHYDROFURIL - METHYL) - 2 - THIOXANTINE. PHARMACEUTICAL COMPOSITIONS. |
US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
JP5757604B2 (en) * | 2010-02-05 | 2015-07-29 | ヒガシマル醤油株式会社 | Myeloperoxidase inhibitor |
US9616063B2 (en) | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
US11241406B2 (en) | 2015-08-28 | 2022-02-08 | Nature's Sunshine Products, Inc. | Compositions and methods for acutley raising nitric oxide levels |
KR20200029513A (en) | 2017-07-17 | 2020-03-18 | 아스트라제네카 아베 | MPO inhibitors for use in medicine |
-
2018
- 2018-07-12 KR KR1020207003720A patent/KR20200029513A/en not_active Application Discontinuation
- 2018-07-12 BR BR112019026270-9A patent/BR112019026270A2/en unknown
- 2018-07-12 US US16/631,548 patent/US11246870B2/en active Active
- 2018-07-12 SG SG11202000086PA patent/SG11202000086PA/en unknown
- 2018-07-12 CA CA3068910A patent/CA3068910A1/en active Pending
- 2018-07-12 ES ES18740208T patent/ES2963315T3/en active Active
- 2018-07-12 JP JP2020500882A patent/JP7220193B2/en active Active
- 2018-07-12 CN CN201880046928.XA patent/CN110891572B/en active Active
- 2018-07-12 MA MA049618A patent/MA49618A/en unknown
- 2018-07-12 WO PCT/EP2018/068992 patent/WO2019016074A1/en unknown
- 2018-07-12 AU AU2018304508A patent/AU2018304508B2/en active Active
- 2018-07-12 EP EP18740208.6A patent/EP3654983B1/en active Active
- 2018-07-12 EA EA202090266A patent/EA202090266A1/en unknown
- 2018-07-12 IL IL272043A patent/IL272043B/en unknown
-
2020
- 2020-02-12 ZA ZA2020/00904A patent/ZA202000904B/en unknown
-
2021
- 2021-12-02 US US17/457,269 patent/US11738027B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2018304508B2 (en) | 2021-06-10 |
US20220160715A1 (en) | 2022-05-26 |
AU2018304508A1 (en) | 2020-02-27 |
NZ761505A (en) | 2023-09-29 |
BR112019026270A2 (en) | 2020-06-30 |
EA202090266A1 (en) | 2020-06-05 |
US20200206226A1 (en) | 2020-07-02 |
EP3654983B1 (en) | 2023-08-30 |
JP2020527137A (en) | 2020-09-03 |
EP3654983A1 (en) | 2020-05-27 |
ES2963315T3 (en) | 2024-03-26 |
CN110891572B (en) | 2023-08-15 |
IL272043B (en) | 2022-09-01 |
WO2019016074A1 (en) | 2019-01-24 |
MA49618A (en) | 2020-05-27 |
ZA202000904B (en) | 2023-04-26 |
CA3068910A1 (en) | 2019-01-24 |
US11246870B2 (en) | 2022-02-15 |
IL272043A (en) | 2020-03-31 |
KR20200029513A (en) | 2020-03-18 |
US11738027B2 (en) | 2023-08-29 |
CN110891572A (en) | 2020-03-17 |
JP7220193B2 (en) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
SG11201909041SA (en) | Anti-pd-l1 antibody and use thereof | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer |